|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0650 CAD | 0.00% |
|
-7.14% | - |
| 19/01 | MediPharm Labs CEO David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO | MT |
| 19/01 | Medipharm Labs Corp. Announces CEO Changes, Effective January 23, 2026 | CI |
| Capitalization | 2.76Cr 2.03Cr 1.71Cr 1.56Cr 1.49Cr 183.54Cr 2.86Cr 18Cr 7.2Cr 88Cr 7.6Cr 7.44Cr 308.81Cr | P/E ratio 2025 * |
-3.25x | P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 2.76Cr 2.03Cr 1.71Cr 1.56Cr 1.49Cr 183.54Cr 2.86Cr 18Cr 7.2Cr 88Cr 7.6Cr 7.44Cr 308.81Cr | EV / Sales 2025 * |
0.6x | EV / Sales 2026 * | 0.55x |
| Free-Float |
94.64% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: MediPharm Labs Corp.
| 1 week | -7.14% | ||
| 1 month | -13.33% | ||
| 3 months | -7.14% | ||
| 6 months | -13.33% |
| 1 week | 0.06 | 0.07 | |
| 1 month | 0.06 | 0.08 | |
| Current year | 0.06 | 0.08 | |
| 1 year | 0.06 | 0.12 | |
| 3 years | 0.06 | 0.12 | |
| 5 years | 0.06 | 0.83 | |
| 10 years | 0.06 | 7.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Greg Hunter
CEO | Chief Executive Officer | - | 23/01/2026 |
William Gordon
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2016 |
Kirk Binns
AUD | Comptroller/Controller/Auditor | - | 06/02/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
John Medland
BRD | Director/Board Member | - | 17/06/2025 |
Michael Bumby
BRD | Director/Board Member | 62 | 01/04/2023 |
Chris Halyk
BRD | Director/Board Member | - | 04/08/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | -7.14% | 0.00% | -23.53% | 2.03Cr | ||
| +0.15% | +10.91% | +57.38% | -33.90% | 187.88Cr | ||
| -1.25% | -6.45% | +31.62% | +5.71% | 109.76Cr | ||
| +1.45% | -1.41% | 0.00% | +185.71% | 55Cr | ||
| Average | +0.09% | -7.59% | +22.25% | +33.50% | 88.66Cr | |
| Weighted average by Cap. | -0.08% | -4.47% | +40.18% | +12.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.59Cr 3.37Cr 2.84Cr 2.59Cr 2.47Cr 304.96Cr 4.75Cr 30Cr 12Cr 146.92Cr 13Cr 12Cr 513.1Cr | 5.04Cr 3.7Cr 3.12Cr 2.84Cr 2.71Cr 334.91Cr 5.21Cr 33Cr 13Cr 161.35Cr 14Cr 14Cr 563.49Cr |
| Net income | -75.7L -55.53L -46.8L -42.71L -40.77L -50Cr -78.29L -4.96Cr -1.97Cr -24Cr -2.08Cr -2.04Cr -85Cr | -19.78L -14.51L -12.23L -11.16L -10.65L -13Cr -20.45L -1.3Cr -51.54L -6.33Cr -54.41L -53.29L -22Cr |
| Net Debt | - | - |
Employees
161
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 0.0650 $ | 0.00% | 9,397 |
| 11/26/11 | 0.0650 $ | 0.00% | 61,048 |
| 10/26/10 | 0.0650 $ | 0.00% | 3,09,717 |
| 09/26/09 | 0.0650 $ | -7.14% | 48,166 |
| 06/26/06 | 0.0700 $ | 0.00% | 94,716 |
Sell
Buy

Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0650
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LABS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition

















